
## Kazuo Kubota

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2220814/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	From tumor biology to clinical PET: A review of positron emission tomography (PET) in oncology. Annals of Nuclear Medicine, 2001, 15, 471-486.	2.2	234
2	Advantage of delayed whole-body FDG-PET imaging for tumour detection. European Journal of Nuclear Medicine and Molecular Imaging, 2001, 28, 696-703.	2.1	221
3	Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Annals of Nuclear Medicine, 2009, 23, 783-791.	2.2	111
4	Whole-body fluorodeoxyglucose positron emission tomography/computed tomography in patients with active polymyalgia rheumatica: evidence for distinctive bursitis and large-vessel vasculitis. Modern Rheumatology, 2012, 22, 705-711.	1.8	84
5	Clinical value of whole-body PET/CT in patients with active rheumatic diseases. Arthritis Research and Therapy, 2014, 16, 423.	3.5	81
6	Tumor detection with carbon-11-labelled amino acids. European Journal of Nuclear Medicine and Molecular Imaging, 1984, 9, 136-140.	2.1	76
7	Experimental study for cancer diagnosis with positron-labeled fluorinated glucose analogs: [18F]-2-fluoro-2-deoxy-D-mannose: A new tracer for cancer detection. European Journal of Nuclear Medicine and Molecular Imaging, 1982, 7, 294-297.	2.1	71
8	FDG-PET for the diagnosis of fever of unknown origin: a Japanese multi-center study. Annals of Nuclear Medicine, 2011, 25, 355-364.	2.2	68
9	Clinical Value of FDG-PET/CT for the Evaluation of Rheumatic Diseases: Rheumatoid Arthritis, Polymyalgia Rheumatica, and Relapsing Polychondritis. Seminars in Nuclear Medicine, 2017, 47, 408-424.	4.6	66
10	FDG PET for rheumatoid arthritis: basic considerations and wholeâ€body PET/CT. Annals of the New York Academy of Sciences, 2011, 1228, 29-38.	3.8	65
11	Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: a case series and literature review. Rheumatology, 2014, 53, 1482-1490.	1.9	64
12	Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. Nuclear Medicine and Biology, 2011, 38, 347-351.	0.6	63
13	Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals. European Journal of Nuclear Medicine and Molecular Imaging, 1983, 8, 258-261.	2.1	56
14	Differences in fluorodeoxyglucose positron emission tomography/computed tomography findings between elderly onset rheumatoid arthritis and polymyalgia rheumatica. Modern Rheumatology, 2015, 25, 546-551.	1.8	53
15	Glucose uptake by individual skeletal muscles during running using whole-body positron emission tomography. European Journal of Applied Physiology, 2000, 83, 297-302.	2.5	51
16	Clinical value of <sup>18</sup> F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: A seven-case series and review of the literature. Modern Rheumatology, 2014, 24, 645-650.	1.8	47
17	Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT. Rheumatology International, 2014, 34, 1545-1554.	3.0	43
18	Lesion-based analysis of 18F-FDG uptake and 111In-Pentetreotide uptake by neuroendocrine tumors. Annals of Nuclear Medicine, 2014, 28, 1004-1010.	2.2	42

Каzuo Кивота

#	Article	IF	CITATIONS
19	Clinical impact of 18F-FDG PET/CT on the management and diagnosis of infectious spondylitis. Nuclear Medicine Communications, 2010, 31, 691-698.	1.1	32
20	Relationship between trait anxiety, brain activity and natural killer cell activity in cancer patients: a preliminary PET study. Psycho-Oncology, 2001, 10, 541-546.	2.3	28
21	Impact of FDG-PET findings on decisions regarding patient management strategies: a multicenter trial in patients with lung cancer and other types of cancer. Annals of Nuclear Medicine, 2015, 29, 431-441.	2.2	28
22	Hypometabolism in the limbic system of cancer patients observed by positron emission tomography. , 1999, 8, 283-286.		26
23	Experimental studies on myocardial glucose metabolism of rats with 18F-2-fluoro-2-deoxy-d-glucose. European Journal of Nuclear Medicine and Molecular Imaging, 1985, 10, 341-5.	2.1	25
24	Constrictive tuberculous pericarditis diagnosed using 18F-fluorodeoxyglucose positron emission tomography: a report of two cases. Annals of Nuclear Medicine, 2010, 24, 421-425.	2.2	19
25	Reproducibility of PET brain mapping of cancer patients. , 2000, 9, 157-163.		15
26	Comparison of 18F-FDG PET/CT and 67Ga-SPECT for the diagnosis of fever of unknown origin: a multicenter prospective study in Japan. Annals of Nuclear Medicine, 2021, 35, 31-46.	2.2	12
27	Clinical Role of FDG PET/CT for Methotrexate-Related Malignant Lymphoma. Clinical Nuclear Medicine, 2011, 36, 533-537.	1.3	11
28	[18F]FDG uptake in axillary lymph nodes and deltoid muscle after COVID-19 mRNA vaccination: a cohort study to determine incidence and contributing factors using a multivariate analysis. Annals of Nuclear Medicine, 2022, 36, 340-350.	2.2	11
29	Effects of smoking on regional cerebral blood flow in cerebral vascular disease patients and normal subjects Tohoku Journal of Experimental Medicine, 1987, 151, 261-268.	1.2	7
30	Value of Carotid Artery Tenderness for the Early Diagnosis of Takayasu Arteritis. Internal Medicine, 2012, 51, 3431-3434.	0.7	3
31	Validation for performing 11C-methionine and 18F-FDG-PET studies on the same day. Nuclear Medicine Communications, 2012, 33, 297-304.	1.1	2
32	A Quantitative Approach of Abdominal Aortic Atherosclerosis with X-ray Computed Tomography. The Journal of Japan Atherosclerosis Society, 1983, 11, 463-466.	0.0	2
33	FDG-PET/CT for Large-Vessel Vasculitis. , 2020, , 115-146.		Ο
34	FDG-PET/CT in Patients with Inflammation or Fever of Unknown Origin (IUO and FUO). , 2020, , 43-55.		0